Reuters logo
BRIEF-Arbor Pharma and Debiopharm announce U.S. FDA approval for Triptodur
June 30, 2017 / 12:27 PM / 3 months ago

BRIEF-Arbor Pharma and Debiopharm announce U.S. FDA approval for Triptodur

June 30 (Reuters) - Arbor Pharmaceuticals LLC

* Arbor pharmaceuticals, llc and debiopharm international sa announce u.s. Fda approval for triptodur™, triptorelin 6-month formulation, in the treatment of central precocious puberty (cpp) Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below